AU5300199A - Method and kit for the determination of analyte concentration in blood - Google Patents
Method and kit for the determination of analyte concentration in blood Download PDFInfo
- Publication number
- AU5300199A AU5300199A AU53001/99A AU5300199A AU5300199A AU 5300199 A AU5300199 A AU 5300199A AU 53001/99 A AU53001/99 A AU 53001/99A AU 5300199 A AU5300199 A AU 5300199A AU 5300199 A AU5300199 A AU 5300199A
- Authority
- AU
- Australia
- Prior art keywords
- blood
- sample
- analyte
- level
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008280 blood Substances 0.000 title claims abstract description 128
- 210000004369 blood Anatomy 0.000 title claims abstract description 127
- 239000012491 analyte Substances 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 69
- 210000004209 hair Anatomy 0.000 claims abstract description 59
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 37
- 210000003296 saliva Anatomy 0.000 claims abstract description 34
- 210000002700 urine Anatomy 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 54
- 239000008103 glucose Substances 0.000 claims description 54
- 239000012503 blood component Substances 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 32
- 102000001554 Hemoglobins Human genes 0.000 claims description 30
- 108010054147 Hemoglobins Proteins 0.000 claims description 30
- 210000003722 extracellular fluid Anatomy 0.000 claims description 27
- 238000005259 measurement Methods 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 230000002934 lysing effect Effects 0.000 claims description 10
- 210000000601 blood cell Anatomy 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 231100000640 hair analysis Toxicity 0.000 claims description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 7
- 210000003780 hair follicle Anatomy 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 18
- 239000012530 fluid Substances 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000004020 luminiscence type Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- -1 for example Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 108091005996 glycated proteins Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 244000153158 Ammi visnaga Species 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009535 clinical urine test Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000607618 Vibrio harveyi Species 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12588098A IL125880A (en) | 1998-08-21 | 1998-08-21 | Method for the determination of analyte concentration in blood |
| IL125880 | 1998-08-21 | ||
| PCT/IL1999/000447 WO2000011469A1 (en) | 1998-08-21 | 1999-08-19 | Method and kit for the determination of analyte concentration in blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5300199A true AU5300199A (en) | 2000-03-14 |
Family
ID=11071875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53001/99A Abandoned AU5300199A (en) | 1998-08-21 | 1999-08-19 | Method and kit for the determination of analyte concentration in blood |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7060453B1 (enExample) |
| EP (1) | EP1105727B1 (enExample) |
| JP (1) | JP2002523744A (enExample) |
| AT (1) | ATE283479T1 (enExample) |
| AU (1) | AU5300199A (enExample) |
| DE (1) | DE69922213T2 (enExample) |
| IL (1) | IL125880A (enExample) |
| WO (1) | WO2000011469A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL138788A0 (en) * | 2000-09-29 | 2001-10-31 | Falk Fish | Method and kit for the transdermal determination of analyte concentration in blood |
| US8150628B2 (en) | 2005-12-30 | 2012-04-03 | The Invention Science Fund I, Llc | Establishing a biological recording timeline by artificial marking |
| US20070156345A1 (en) * | 2005-12-30 | 2007-07-05 | Hyde Roderick A | Modulating a biological recording with another biological recording |
| TW200801513A (en) * | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| EP3667325B1 (en) | 2013-08-28 | 2023-10-04 | Psychemedics Corporation | Integrity testing of hair samples |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS175782B1 (enExample) | 1974-10-16 | 1977-05-31 | ||
| CS176664B1 (enExample) | 1975-02-14 | 1977-06-30 | ||
| US4615982A (en) | 1984-12-11 | 1986-10-07 | Lawrence Paul J | Fecal occult blood test |
| US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
| US5056521A (en) | 1989-06-29 | 1991-10-15 | Health Craft International, Inc. | Method for monitoring glucose level |
| US5103836A (en) | 1990-02-28 | 1992-04-14 | Epitope, Inc. | Oral collection device and kit for immunoassay |
| US5089420A (en) * | 1990-01-30 | 1992-02-18 | Miles Inc. | Composition, device and method of assaying for a peroxidatively active substance utilizing amine borate compounds |
| US5268148A (en) | 1990-12-18 | 1993-12-07 | Saliva Diagnostic Systems, Inc. | Saliva sampling device and sample adequacy system |
| US5714341A (en) | 1994-03-30 | 1998-02-03 | Epitope, Inc. | Saliva assay method and device |
| US6102872A (en) | 1997-11-03 | 2000-08-15 | Pacific Biometrics, Inc. | Glucose detector and method |
-
1998
- 1998-08-21 IL IL12588098A patent/IL125880A/xx not_active IP Right Cessation
-
1999
- 1999-08-19 US US09/763,415 patent/US7060453B1/en not_active Expired - Lifetime
- 1999-08-19 WO PCT/IL1999/000447 patent/WO2000011469A1/en not_active Ceased
- 1999-08-19 JP JP2000566674A patent/JP2002523744A/ja not_active Ceased
- 1999-08-19 AT AT99938497T patent/ATE283479T1/de not_active IP Right Cessation
- 1999-08-19 DE DE69922213T patent/DE69922213T2/de not_active Expired - Lifetime
- 1999-08-19 AU AU53001/99A patent/AU5300199A/en not_active Abandoned
- 1999-08-19 EP EP99938497A patent/EP1105727B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL125880A0 (en) | 1999-04-11 |
| US7060453B1 (en) | 2006-06-13 |
| JP2002523744A (ja) | 2002-07-30 |
| EP1105727A1 (en) | 2001-06-13 |
| WO2000011469A1 (en) | 2000-03-02 |
| DE69922213D1 (de) | 2004-12-30 |
| IL125880A (en) | 2000-11-21 |
| ATE283479T1 (de) | 2004-12-15 |
| DE69922213T2 (de) | 2005-11-24 |
| EP1105727B1 (en) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7004901B2 (en) | Method and kit for the transdermal determination of analyte concentration in blood | |
| JP3527741B2 (ja) | 体液試料中の溶血を検出するための方法および装置 | |
| Verde et al. | Use of N, N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma | |
| Campanella et al. | New biosensor for superoxide radical used to evidence molecules of biomedical and pharmaceutical interest having radical scavenging properties | |
| Gomez et al. | Normal reference-intervals for 20 biochemical variables in healthy infants, children, and adolescents. | |
| Heller et al. | A simplified assay for porphyrins in whole blood | |
| JP2015509361A (ja) | 酵素法を利用したヘモグロビンＡ１ｃ定量分析のための溶血試薬組成物 | |
| CN107884401A (zh) | 消除脂血干扰的葡萄糖氧化酶测定方法 | |
| CN101503732A (zh) | 一种葡萄糖氧化酶单一液体测定试剂 | |
| Bryszewska et al. | Association between the glycation of erythrocyte membrane proteins and membrane fluidity | |
| JPH04212060A (ja) | 全血の分離及び検定のための装置及び方法 | |
| CA2092917C (en) | Hair analysis method | |
| EP1105727B1 (en) | Method and kit for the determination of analyte concentration in blood | |
| JPH0695954B2 (ja) | クレアチニン又はクレアチンの測定要素及び測定方法 | |
| Lopes et al. | Glucose concentration in dairy cows measured using 6 handheld meters designed for human use | |
| KR20070011416A (ko) | 저밀도 리포 단백질 중 콜레스테롤의 멀티 정량법 | |
| AU2005238099B2 (en) | Direct assay of skin cholesterol in skin samples removed by tape stripping | |
| KR102081522B1 (ko) | 혈액 분석 방법 및 혈액 검사 키트 | |
| Sobin et al. | Histochemical characterization of the aging microvasculature in the human and other mammalian and non-mammalian vertebrates by the periodic acid-Schiff reaction | |
| RU2012878C1 (ru) | Универсальная тест-полоска для определения содержания глюкозы в моче, крови и других биологических жидкостях | |
| Wikman-Coffelt et al. | Influence of myocardial isomyosins on cardiac performance and oxygen consumption | |
| Chen et al. | Fluorometry of Selenium in Human Hair, Urine and Blood: A Single-Tube Process for Submicrogram Determination of Selenium | |
| EP1711831B1 (de) | Diagnose von sepsis durch selektive bestimmung der konzentration der cu/zn superoxiddismutase (cu/zn sod) in patientenproben | |
| JP3598273B2 (ja) | ヘモグロビン妨害を排除しつつアルカリホスファターゼを測定する方法 | |
| WO1993013219A1 (fr) | Composition de determination d'ions calcium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |